Compare AbbVie Inc (ABBV) vs Corning Incorporated (GLW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Corning Incorporated — how do they compare? AbbVie Inc trades at $252.93 (market cap $449.91B), while Corning Incorporated trades at $184 (market cap $159.55B). The key difference: AbbVie Inc is far larger — about 2.8× Corning Incorporated's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | GLW | |
|---|---|---|
Market Cap | $449.91B | $159.55B |
Sector | Health | Technology |
52-Week High | $261.07 | $255.79 |
52-Week Low | $184.85 | $51.60 |
Enterprise Value | $513.38B | $167.71B |
Dividend Yield | 2.72% | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Corning Inc. (GLW) trades at $185.38, down 5.75% amid recent AI-related stock volatility, yet maintains strong fundamentals with Q1 2026 EPS beating estimates at $0.70. Revenue grew to $15.63B in 2025, with net income margin improving to 10.21%. Technical indicators show a bullish overall signal despite near-term bearish moving averages, with key support at $185. Recent news highlights AI-driven fiber demand as a growth catalyst, though competition and China exposure pose risks.
The outlook remains positive with a consensus price target of $206.60, implying 11.4% upside, supported by 54% analyst buy ratings. Risks include high valuation multiples (P/E 93.65) and dependency on AI infrastructure spending cycles. Institutional sentiment is bullish, but investors should monitor earnings consistency and macroeconomic pressures on tech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
